ROR1 and neoplasm: GNC-035 targets CD3, 4-1BB, PD-L1, and ROR1 providing T-cell activation (CD3), co-stimulation (4-1BB), checkpoint inhibition (PD-L1), and tumor specificity (ROR1) within a single molecule [86].